BSN Capital Partners’s Idexx Laboratories IDXX Stock Holding History

BSN Capital Partners’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,945	Closed	-$7.5M	–	32
2024 Q3	$7.5M	Buy	+15,945	New	+$7.75M	1.46%	31

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BSN Capital Partners's IDXX Position: Q4 2024 in Review

BSN Capital Partners sold out of Idexx Laboratories (IDXX) in Q4 2024, closing a stake of 15,945 shares — an estimated $7.5M sold.

BSN Capital Partners first reported a position in IDXX in Q3 2024 and held it in 1 quarter. The position peaked at $7.5M in Q3 2024. 1,123 funds tracked by Wall St. Rank hold IDXX as of Q4 2024.

BSN Capital Partners reported no remaining Idexx Laboratories position as of Q4 2024 after selling out during the quarter.
BSN Capital Partners sold 15,945 Idexx Laboratories shares in Q4 2024, an estimated $7.5M.
BSN Capital Partners first reported a position in Idexx Laboratories in Q3 2024 and held it in 1 quarter.
BSN Capital Partners's Idexx Laboratories position peaked at $7.5M in Q3 2024.
1,123 funds tracked by Wall St. Rank held Idexx Laboratories as of Q4 2024.

Based on BSN Capital Partners's 13F filing for Q4 2024, filed 28 Jan 2025.